Back to Journals » Clinical Pharmacology: Advances and Applications » Volume 5 » Supplement 1

Immunocytokines: a review of molecules in clinical development for cancer therapy

Authors List T, Neri D

Received 31 May 2013

Accepted for publication 27 June 2013

Published 20 August 2013 Volume 2013:5(Supplement 1) Pages 29—45

DOI https://doi.org/10.2147/CPAA.S49231

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 5


Thomas List, Dario Neri

Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Zurich, Switzerland

Abstract: The concept of therapeutically enhancing the immune system’s responsiveness to tumors is long standing. Several cytokines have been investigated in clinical trials for their therapeutic activity in cancer patients. However, substantial side effects and unfavorable pharmacokinetic properties have been a major drawback hampering the administration of therapeutically relevant doses. The use of recombinant antibody–cytokine fusion proteins promises to significantly enhance the therapeutic index of cytokines by targeting them to the site of disease. This review aims to provide a concise and complete overview of the preclinical data and clinical results currently available for all immunocytokines having reached clinical development.

Keywords: antibodies, cytokines, preclinical

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]